Sequential treatment with afatinib and osimertinib in real-world patients with EGFR mutation-positive advanced NSCLC: the GioTag study

被引：1

作者：

Hochmair, M. ^{[1
,2
]}

Cufer, T. ^{[3
]}

Morabito, A. ^{[4
]}

Hao, D. ^{[5
]}

Yang, C. ^{[6
]}

Soo, R. ^{[7
]}

Yang, J. C. ^{[8
]}

Gucalp, R. Rasim ^{[9
]}

Halmos, B. ^{[10
]}

Wang, L. ^{[11
]}

Golembesky, A. ^{[12
]}

Maerten, A. ^{[13
]}

O'Byrne, K. ^{[14
]}

机构：

[1] Otto Wagner Hosp, Dept Resp & Crit Care Med, Vienna, Austria

[2] Otto Wagner Hosp, Ludwig Boltzmann Inst COPD & Resp Epidemiol, Vienna, Austria

[3] Univ Ljubljana, Univ Clin Golnik, Ljubljana, Slovenia

[4] Fdn G Pascale IRCCS, Ist Nazl Tumori, Thorac Med Oncol, Naples, Italy

[5] Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada

[6] Chang Gung Mem Hosp, Dept Thorac Med, Taoyuan, Taiwan

[7] Natl Univ Singapore Hosp, Dept Haematol Oncol, Singapore, Singapore

[8] Natl Taiwan Univ, Natl Taiwan Univ Hosp, Ctr Canc, Taipei, Taiwan

[9] Montefiore Albert Einstein Canc Ctr, Dept Oncol, Bronx, NY USA

[10] Montefiore Albert Einstein Canc Ctr, Dept Oncol, Bronx, NY USA

[11] Boehringer Ingelheim Taiwan Ltd, Global Clin Operat, Taipei, Taiwan

[12] Boehringer Ingelheim Int GmbH, Epidemiol, Ingelheim, Germany

[13] Boehringer Ingelheim Int GmbH, Oncol Med, Ingelheim, Germany

[14] Princess Alexandra Hosp, Med Oncol, Brisbane, Qld, Australia

来源：

关键词：

D O I：

10.1016/S0169-5002(19)30130-8

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S37 / S37

页数：1